-
JBCRG-12
Effect of the genetic polymorphism of drug-metabolizing enzymes on blood concentrations of the drug in endocrine therapy for breast cancer
- Status
-
Study Closed
- Objectives
-
To identify CYP2D6 genetic polymorphism as a potential predictive factor in patients with hormone receptive positive breast cancer, for whom endocrine therapy with tamoxifen or toremifene was indicated, in order to determine blood concentrations of active metabolites. Relationships with adverse events and clinical effects were also examined.
- Subjects
-
- Endpoints
-
Primary Endpoint: Relationship between CYP2D6 genetic polymorphism and blood concentrations of anti-estrogen active metabolites, Secondary endpoints : Relationship between adverse events (hot flush) and blood concentrations of anti-estrogen active metabolites
- Trial Period
-
2 years entry, follow up （up to the end of last drug concentration blood collection case)
- Lead Principal Investigator
-
Hiroshi Ishiguro(Outpatient Oncology Unit, Kyoto University Hospital)
- Target Sample Size
-
tamoxifen(100) and toremifen(100)
- Regimen
-
tamoxifen or toremifen
- Source of Funding
-
JBCRG
- Conference Presentation
-
Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (JBCRG-12,15)
- Articles and Publications
-
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (JBCRG-12/15)
- UMIN-ID
-
UMIN000001665
- jRCT
-
- Memo
-
- COI Disclosure
-
